No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis

Abstract Objective Patients with cystic fibrosis are more susceptible than members of the general population to lung infections. Infections with Pseudomonas aeruginosa require particular attention, because they may accelerate the deterioration of lung function if not adequately treated. This study a...

Full description

Bibliographic Details
Main Authors: F. Claude, I. Rochat, G. M. Hafen
Format: Article
Language:English
Published: BMC 2019-03-01
Series:BMC Research Notes
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13104-019-4157-8
id doaj-808d176250db41aa99599a56487ae1cf
record_format Article
spelling doaj-808d176250db41aa99599a56487ae1cf2020-11-25T00:06:35ZengBMCBMC Research Notes1756-05002019-03-011211610.1186/s13104-019-4157-8No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosisF. Claude0I. Rochat1G. M. Hafen2Faculty of Biology and Medicine, University of LausanneDepartment of Pediatrics, Respiratory Unit, Centre Hospitalier Universitaire VaudoisDepartment of Pediatrics, Respiratory Unit, Centre Hospitalier Universitaire VaudoisAbstract Objective Patients with cystic fibrosis are more susceptible than members of the general population to lung infections. Infections with Pseudomonas aeruginosa require particular attention, because they may accelerate the deterioration of lung function if not adequately treated. This study assessed the eradication rate of P. aeruginosa primoinfections, with a protocol of inhaled tobramycin and oral ciprofloxacin over a 3 months’ period. Results Retrospective single-center study from June 1st, 2007 to December 31st, 2015. Inclusion of 28 pediatric patients (11 females, 17 males), with a total of 49 primoinfections. Overall success rate of 67.3%, which is similar or even inferior to figures published in the literature.http://link.springer.com/article/10.1186/s13104-019-4157-8Cystic fibrosisPseudomonas aeruginosaPrimoinfectionEradication protocol
collection DOAJ
language English
format Article
sources DOAJ
author F. Claude
I. Rochat
G. M. Hafen
spellingShingle F. Claude
I. Rochat
G. M. Hafen
No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis
BMC Research Notes
Cystic fibrosis
Pseudomonas aeruginosa
Primoinfection
Eradication protocol
author_facet F. Claude
I. Rochat
G. M. Hafen
author_sort F. Claude
title No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis
title_short No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis
title_full No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis
title_fullStr No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis
title_full_unstemmed No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis
title_sort no benefit of longer eradication therapy of pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis
publisher BMC
series BMC Research Notes
issn 1756-0500
publishDate 2019-03-01
description Abstract Objective Patients with cystic fibrosis are more susceptible than members of the general population to lung infections. Infections with Pseudomonas aeruginosa require particular attention, because they may accelerate the deterioration of lung function if not adequately treated. This study assessed the eradication rate of P. aeruginosa primoinfections, with a protocol of inhaled tobramycin and oral ciprofloxacin over a 3 months’ period. Results Retrospective single-center study from June 1st, 2007 to December 31st, 2015. Inclusion of 28 pediatric patients (11 females, 17 males), with a total of 49 primoinfections. Overall success rate of 67.3%, which is similar or even inferior to figures published in the literature.
topic Cystic fibrosis
Pseudomonas aeruginosa
Primoinfection
Eradication protocol
url http://link.springer.com/article/10.1186/s13104-019-4157-8
work_keys_str_mv AT fclaude nobenefitoflongereradicationtherapyofpseudomonasaeruginosaprimoinfectionsinpediatriccysticfibrosis
AT irochat nobenefitoflongereradicationtherapyofpseudomonasaeruginosaprimoinfectionsinpediatriccysticfibrosis
AT gmhafen nobenefitoflongereradicationtherapyofpseudomonasaeruginosaprimoinfectionsinpediatriccysticfibrosis
_version_ 1725421299362168832